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Abstract
Background: Recent data show aberrant and altered expression of regulatory noncoding micro
(mi) RNAs in prostate cancer (PCa). A large number of miRNAs are encoded in organized intronic
clusters within many protein coding genes. While expression profiling studies of miRNAs are
common place, little is known about the host gene and their resident miRNAs coordinated
expression in PCa cells. Furthermore, whether expression of a subset of miRNAs is distinct in
androgen-responsive and androgen-independent cells is not clear. Here we have examined the
expression of mature miRNAs of miR 17–92, miR 106b-25 and miR 23b-24 clusters along with their
host genes C13orf25, MCM7 and AMPO respectively in PCa cell lines.
Results: The expression profiling of miRNAs and host genes was performed in androgen-sensitive
MDA PCa 2b and LNCaP as well as in androgen-refractory PC-3 and DU 145 cell culture models
of PCa. No significant correlation between the miRNA expression and the intrinsic hormone-
responsive property of PCa cells was observed. Androgen-sensitive MDA PCa 2b cells exhibited
the highest level of expression of most miRNAs studied in this report. We found significant
expression variations between host genes and their resident miRNAs. The expressions of
C13orf25 and miR 17–92 cluster as well as MCM7 and miR 106b-25 cluster did not reveal
statistically significant correlation, thus suggesting that host genes and resident miRNAs may be
expressed independent of each other.
Conclusion:  Our results suggest that miRNA expression profiles may not predict intrinsic
hormone-sensitive environment of PCa cells. More importantly, our data indicate the possibility of
additional novel mechanisms for intronic miRNA processing in PCa cells.
Background
Prostate cancer (PCa) is the most frequently diagnosed
cancer and the second leading cause of death among
American men [1]. The initial stage of PCa is androgen-
dependent; hence, androgen blockade is the mainstay of
therapy. Although androgen ablation therapy is effective
in causing regression of prostate tumors, it produces only
temporary remissions. The therapy eventually fails and
PCa transits to the androgen-refractory or androgen-inde-
pendent stage, a lethal form with a fatal prognosis [2].
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Although several mechanisms have been proposed for
explaining the pathogenesis of PCa, the molecular mech-
anisms underlying the critical transition from androgen-
dependence to androgen-independence of these tumors
are poorly understood [reviewed in [3,4]].
Regulatory noncoding microRNAs (miRNAs) play a criti-
cal role in the regulation of gene expression [5] and are
potential candidates for studying their role in the progres-
sion of PCa to androgen-independent stage. miRNAs con-
trol gene expression by binding to the complementary
sites in the 3' untranslated regions (3' UTRs) of target
mRNAs and triggering either translational inhibition or
mRNA degradation by a molecular mechanism which is a
subject of intense investigation [6-9]. Aberrant expression
of miRNAs has been correlated with the metastatic poten-
tial of melanoma [10,11], lymphoma [12-15], gastric [16-
18], ovarian [19-21], breast [22,23] and colorectal cancers
[24-26]. Furthermore, miRNA expression or lack thereof,
is associated with the disease progression of urogenital
cancers including bladder, kidney [27,28] and prostate
[29,30]. Recent studies have demonstrated the aberrant
expression of miRNAs in PCa tissues and cell lines [30-34]
and differential expression of a miRNA in androgen-
dependent and androgen-independent PCa cells [29].
Furthermore, androgen-regulated miRNAs may play a role
in the transition of PCa to the androgen-independent
stage [35]. Therefore, the role of miRNAs and their differ-
ential signature expression patterns in androgen-depend-
ent and androgen-independent PCa cells requires a closer
validation.
Gene expression modulating miRNAs are encoded in
diverse genomic locations including intergenic regions,
introns of protein-coding genes and introns/exons of
noncoding RNA genes [36]. Approximately one third of
experimentally identified human miRNAs are encoded in
the introns of annotated protein coding genes [37,38]. It
is likely that the intronic miRNAs are processed from the
same primary transcript as the precursor mRNAs and thus,
their expression levels are regulated by the expression of
the host mRNA [39]. Interestingly, over 40% of human
miRNAs are organized in evolutionarily conserved clus-
ters suggesting that the clustering propensity of miRNAs
may have a significant biological role [36-38,40,41].
Accumulating evidence suggests that clustered miRNAs
are transcribed as polycistronic transcripts and thus have
similar levels of expression. The miRNA clusters located in
the introns of host genes present an especially interesting
scenario by adding another level of co-regulation with the
host mRNA expression. Although several miRNAs includ-
ing some clustered miRNAs are functionally involved in
the process of carcinogenesis [42-44], the phenomenon of
miRNA clustering and their expression analysis vis-à-vis
host gene expression has not been extensively investigated
in PCa cells.
We investigated the expression of intronic miRNA clusters
with respect to their host transcript expressions in PCa
cells representing two distinct stages of PCa. The panel of
PCa cell lines included two androgen-sensitive (MDA PCa
2b and LNCaP) and two androgen-independent (PC-3
and DU 145) cell lines. MDA PCa 2b and LNCaP cell lines
are derived from bone and lymph node metastasis respec-
tively [45,46]. These cell lines express androgen receptor
(AR) and PCa biomarker, prostate specific antigen (PSA)
[47]. On the other hand PC-3 and DU 145 cell lines lack
AR, do not express PSA and do not have androgen
response [47]. Host genes and their resident miRNA clus-
ters were selected based on their potential relevance to
cancer. Three intronic miRNA clusters were analyzed in
this study: (i) miR 17–92 cluster, (ii) miR 106b-25 cluster
and (iii) miR 23b-24 cluster.
The human miR 17–92 cluster is comprised of six miRNAs
and is located in the third intron of C13orf25 gene at
13q31.3 (Figure 1A). A growing body of evidence indi-
cates that the miR 17–92 cluster acts as a potential onco-
gene and is mechanistically involved in tumorigenesis
[48-50]. The miR 106b-25 cluster consists of three miR-
NAs and is located in the 13th intron of MCM7 (minichro-
mosome maintenance protein 7) gene on human
chromosome 7 (Figure 2A). The miRNAs of this cluster
share a high degree of sequence homology with the miR-
NAs of the miR17–92 cluster, thus suggesting the possibil-
ity of overlapping cellular functions of the two miRNA
clusters. Furthermore, overexpression of MCM7 has been
associated with PCa progression and recurrence [51]. In
addition, miR 106b-25 is believed to be involved in a vari-
ety of cancers, suggesting its biological significance in car-
cinogenesis [16]. The miR 23b-24 cluster resides in intron
15 of the Aminopeptidase O (AMPO) gene on human
chromosome 9 and consists of three member miRNAs:
miR 23b, miR 24 and miR 27b (Figure 3A). The aberrant
expression of miRNA members of miR 23b-24 cluster has
been reported in some cancers [27]. miR 24 appears to
inhibit erythroid differentiation [52] and a role for miR
27b has been indicated in angiogenesis [53]. The differen-
tial expression of these miRNA clusters has not been stud-
ied systematically in prostate carcinogenesis.
Furthermore, whether the member miRNAs are differen-
tially expressed in androgen-dependent and androgen-
refractory PCa is undetermined.
We hypothesized that these miRNAs may have unique
expression patterns in androgen-sensitive and androgen-
refractory cell culture models of PCa. Hence, we character-
ized the expression of the miRNAs and their host genes inCancer Cell International 2009, 9:21 http://www.cancerci.com/content/9/1/21
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PCa cell lines by northern blot and real-time quantitative
PCR techniques.
Results
Expression Profiling of miR 17–92, 106b-25 and 23b-24 
Clusters in Androgen-Dependent and Androgen-
Refractory PCa Cell Lines by Northern Blotting
Two distinct stages of PCa are recapitulated in a variety of
human PCa cell culture models. These cells lines are char-
acterized in terms of their androgen sensitivity to account
for their cell invasion and metastasis properties. As shown
in Figures 1 to 3, we characterized the expression of
miRNA members of three clusters in PCa cell lines by
Northern blotting. A summary of the relative miRNA
expression is summarized in table 1. The oncomir cluster
17–92 is encoded in the third intron of the C13orf25 gene
(Figure 1A) [12]. As evidenced by the northern blotting
experiment, miRNA members of the miR 17–92 cluster
show a characteristic differential expression profile for
each cell line studied (Figure 1B). All miRNA members of
this cluster were expressed in androgen-sensitive MDA
PCa 2b and LNCaP cells, albeit with varied levels (Figure
1B). However, not all the members were expressed in hor-
monal-refractory PC-3 and DU 145 cell lines e.g. miR18a
and miR19a expression was not detected by northern blot
analysis in these hormonal-refractory PCa cell lines.
miRs19b, 17-5p, 20a and 92a were found to be expressed
in all four cell lines, albeit the expression was at lower lev-
els in hormonal-refractory cells as compared to hormone-
sensitive cells (Figure 1B). The miR 17–92 cluster mem-
bers on chromosome 13 share a high level of sequence
homology with the miRNAs of two paralogous clusters,
namely, miR 106b-25 and miR 106a-363 present on chro-
mosome 7 and chromosome X respectively. Sequence
homology between the miRNAs of these clusters is shown
in Figures 1C and 2C.
The miR 106b-25 cluster is encoded in intron 13 of
MCM7 gene and contains three miRNA coding genes. The
organization of miRNA genes in intron 13 is shown in Fig-
ure 2A. The northern blot analyses of miR 106b-25 cluster
revealed similar levels of expression of all three miRNAs
in the four cell lines (Figure 2B).
The miR 23b-24 cluster contains three miRNA coding
genes located in the intron 15 of AMPO gene. The struc-
ture of miR 23b-24 cluster is shown in Figure 3A. The
miR 17–92 cluster structure and expression Figure 1
miR 17–92 cluster structure and expression. (A) Sche-
matic representation of miR 17–92 cluster. Six miRNAs are 
expressed from intron 3 of C13orf25 gene (Ex = exon). The 
unfilled boxes correspond to precursor miRNAs and the 
solid thick black line within each box corresponds to mature 
miRNA. (B) The expression patterns of member miRNAs of 
miR 17–92 cluster in four PCa cell lines as evaluated by 
northern blotting (MDA = MDA PCa 2b). (C) Pairwise align-
ment of miRNAs. The figure reveals sequence similarities 
between miRNAs of paralogous clusters. Identical sequence 
between two miRNAs is shown by asterisks below the com-
parison and letters in bold correspond to sequence variation. 
miRs 18b and 20b shown in the alignments are derived from 
miR106a-363 cluster on chromosome X. The miR 106a-363 
cluster contains six miRNAs, namely, 106a, 18b, 20b, 19b-2, 
92a-2 and 363. The mature forms of miR 19b and miR 92a 
are expressed from both miR17–92 and miR106a-363 clus-
ters.
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miR106b-25 cluster structure and expression Figure 2
miR106b-25 cluster structure and expression. (A) 
Genomic organization of miR106b-25 cluster in intron 13 of 
MCM7 gene. Precursor miRNAs are represented as unfilled 
boxes and the solid thick black line within each box corre-
sponds to mature miRNA (Ex = exon). (B) Representative 
northern blot showing the expression of miR 106b-25 cluster 
in PCa cell lines (MDA = MDA PCa 2b). (C) Sequence com-
parison of miRNAs. Identical sequence between two miR-
NAs is shown by asterisks below the comparison and letters 
in bold correspond to sequence variation. miR 106a is 
expressed from miR106a-363 cluster on chromosome X. 
miR 92a is derived from both miR17–92 and miR106a-363 
clusters. miR 20a is also expressed from the miR 17–92 clus-
ter.
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miRNA members of miR 23b-24 cluster demonstrated
varied degree of expression levels as observed by signal
intensities (Figure 3B). All three member miRNAs are
expressed at higher levels in androgen-independent PC-3
and DU 145 cell lines as compared to androgen-depend-
ent cells. The miR 23b-24 cluster on chromosome 9 shares
sequence homology with miR 23a-24 cluster on chromo-
some 19. The miR 23b and 27b sequences (miR 23b-24
cluster) differ by one nucleotide from the miR 23a and
27a sequences in the miR 23a-24 cluster (Figure 3C) and
the two miRs 24 arising from both the clusters have an
identical sequence. Hence, it is possible that the signal
intensities of miRNA expression levels observed by north-
ern blotting may correspond to some degree of cross
hybridization to the paralog counterparts of miRNAs.
In summary, northern blot analyses of miRNA clusters in
PCa cell lines demonstrated differential expression pat-
terns of 12 miRNAs in the four PCa cell lines. Although it
is a reliable technique, northern blotting cannot accu-
rately estimate the expression of miRNAs having highly
similar sequences. Hence, we sought to quantify the
expression of these miRNAs as well as their host tran-
scripts by reverse transcription and quantitative real-time
PCR. To quantify the expression of mature miRNAs, we
used TaqMan MicroRNA assays [54,55]. This technique
can accurately analyze the expression of related miRNAs
because it can discriminate between similar miRNAs dif-
fering by a single nucleotide [56].
Expression of miR 17–92 Cluster and Host Transcript 
C13orf25
All six miRNA members of the miR 17–92 cluster were sig-
nificantly downregulated (p < 0.01, table 2 & Figure 4A)
in LNCaP, PC-3 and DU 145 cells as compared to their
expression in MDA PCa 2b cells. The expression profile of
the miR 17–92 cluster in LNCaP (androgen-dependent)
cells was similar to that in DU 145 (androgen-independ-
ent) cells instead of matching the miR 17–92 expression
profile in androgen-dependent MDA PCa 2b cells (Figure
4A). The maximum downregulation (upto 20 fold) of
miRNA members was observed in PC-3 (androgen-inde-
pendent) cells and this expression profile was significantly
different from that in the other three cell lines (table 2).
This suggests that the miRNAs of the miR 17–92 cluster
are differentially expressed among the four PCa cell lines
and do not correlate with the intrinsic androgen response
miR23b-24 cluster structure and expression Figure 3
miR23b-24 cluster structure and expression. (A) Three 
miRNAs are encoded in intron 15 of AMPO gene (Ex = 
exon). Precursor miRNAs are represented as unfilled boxes 
and the solid thick black line within each box corresponds to 
mature miRNA. (B) Representative northern blot showing 
the expression of miR 23b-24 in PCa cell lines (MDA = MDA 
PCa 2b). (C) Aligned sequences of mature miRNAs revealing 
the high level of identity. Asterisks correspond to identical 
sequence between two miRNAs and bold letters corre-
sponds to sequence variation. miRs 23a and 27a are 
expressed from the miR 23a-24 cluster on chromosome 19.
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Table 1: Relative expression of miRNAs as determined by northern blots
Cluster Genomic Location Host Gene hsa-miR MDA PCa 2b LNCaP PC3 DU145
17–92 13q31.3 C13orf25 17-5p ++++ +++ ++ ++
18a ++ + - -
19a ++ + - -
19b ++++ +++ + +
20a +++ ++ + +
92a +++ +++ ++ ++
106b-25 7q22.1 MCM7 25 + + + +
93 + + + +
106b ++ ++ ++ ++
23b-24 9q22.32 AMPO 23b + + +++ +++
24 + + ++ ++
27b - - + +
Hybridization signal intensities of each miRNA probe were normalized to the hybridization signal intensities of the U6 snRNA probe and the 
relative expression was scored on an arbitrary scale where (-) and (++++) correspond respectively to undetectable and highest levels of relative 
expression of each miRNA in the four PCa cell lines.Cancer Cell International 2009, 9:21 http://www.cancerci.com/content/9/1/21
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status of PCa cells. Remarkably, although there is a gen-
eral decrease in the expression of miRNA members in the
three cell lines as compared to their expression in MDA
PCa 2b cells, the fold decrease differs widely among clus-
ter members. While the expression of miR 17-5p and miR
92a in PC-3 cells is reduced to approximately half their
levels in MDA PCa 2b cells, the miRs 18a, 19a, 19b and
20a are downregulated by 10–20 fold in PC-3 cells as
compared to their expression in MDA PCa 2b cells (Figure
4A). Likewise, the member miRNAs in LNCaP and DU
145 cells are downregulated in the range of 4–9 folds as
compared to their expression in MDA PCa 2b cells. Within
each cell line, the member miRNAs are expressed at differ-
ent levels with miR 92a being the most abundant in all
cell lines. It is noteworthy that miR 19b and miR 92a are
also derived from a paralogous cluster miR 106a-363 on
chromosome X. Hence, the levels of miRs 19b and 92a
estimated by qRT-PCR do not represent the amount of
these miRNAs processed from the miR 17–92 cluster
alone but instead, represent the total amount of these
miRNAs derived from both clusters.
As seen in Figures 4A and 4B, the expression profile of
C13orf25 transcript in PCa cell lines is distinguishable
from the expression profile of the resident miR 17–92
cluster in the same cell lines. While the C13orf25 mRNA
is approximately 3-fold upregulated (p < 0.01, table 2) in
LNCaP cells as compared to its expression in MDA PCa
2b, PC-3 and DU 145 cells, the member miRNAs of the
miR 17–92 cluster are downregulated in LNCaP cells as
compared to their expression in MDA PCa 2b cells (Fig-
ures 4A &4B). We applied Pearson product-moment cor-
relation test on the C13orf25 and miR 17–92 expression
data and found no significant correlation between the
expression of the host gene C13orf25 and its resident
miRNAs (table 3).
Expression of miR 106b-25 Cluster and Host Transcript 
MCM7
Next, we analyzed the expression of three miRNAs,
namely miR 25, miR 93 and miR 106b, which are mem-
bers of the miR 106b-25 cluster encoded in intron 13 of
MCM 7 gene. The expression of the three miRNA mem-
bers of the miR 106b-25 cluster was significantly reduced
(p < 0.01, table 4) in LNCaP, PC-3 and DU 145 cells as
compared to their expression in MDA PCa 2b cells (Figure
5A). While all the three member miRNAs were downregu-
lated by more than 2-fold in LNCaP and DU 145 cells,
miR 106b was downregulated by approximately 5-fold in
PC-3 cells. miR 25 and miR 93 showed less than 2-fold
downregulation in PC-3 cells as compared to their expres-
sion in MDA PCa 2b cells (Figure 5A). The 106b-25
miRNA cluster expression profile in androgen-dependent
LNCaP cells was significantly different (p < 0.001, table 4)
from that in another androgen-dependent cell line MDA
PCa 2b. Moreover, the miRNA expression profile in PC-3
(androgen-independent) cells was also significantly dif-
ferent (p < 0.01, table 4) from that in DU 145 (androgen-
independent) cells. Hence, the expression of miR 106b-25
cluster does not appear to correlate with the intrinsic
androgen responsiveness of PCa cells.
The comparison of the expression profile of MCM7
mRNA with the expression profile of the resident miR
106b-25 cluster shows no significant correlation between
the host gene and intronic miRNA cluster expression
(table 5). While the member miRNAs were significantly
downregulated in LNCaP, PC-3 and DU 145 cells as com-
pared to their expression in MDA PCa 2b cells (Figure 5A),
the MCM7 mRNA was significantly upregulated in DU
145 cells (p < 0.01, table 4) and PC-3 cells (p < 0.0001,
table 4), and was expressed at similar level in LNCaP cells
as compared to the expression in MDA PCa 2b cells (Fig-
ure 5B).
Expression of miR 23b-24 Cluster and Host Transcript 
AMPO
All three members of miR 23b-24 cluster, namely miR
23b, miR 24 and miR 27b were significantly downregu-
lated by approximately 10 fold (p < 0.01, table 6) in
LNCaP cells as compared to their expression in MDA PCa
2b cells (Figure 6A). While miR 23b and miR 27b were sig-
Table 2: Fold changes in the expressions of C13orf25 mRNA and miR 17–92 cluster in PCa cell lines
LNCaP/MDA PC-3/MDA DU145/MDA PC-3/LNCaP DU145/LNCaP DU145/PC-3
C13orf25 3.35** 0.29*** 0.34**** 0.08** 0.10** 1.16
miR 17-5p 0.15** 0.43** 0.24*** 2.79**** 1.57* 0.56***
miR 18a 0.12**** 0.09**** 0.17**** 0.80 1.38 1.72*
miR 19a 0.19** 0.04** 0.14*** 0.23** 0.73* 3.16*
miR 19b 0.17**** 0.05**** 0.14**** 0.32** 0.82* 2.55***
miR 20a 0.10**** 0.05**** 0.12**** 0.51**** 1.21* 2.35***
miR 92a 0.17*** 0.55*** 0.21*** 3.20**** 1.25** 0.39***
The fold change in the expression levels of the host gene and member miRNAs was determined by ratios of the expression between two cell lines 
(LNCaP/MDA, PC-3/MDA, DU145/MDA, PC-3/LNCaP, DU145/LNCaP and DU145/PC-3). Asterisks indicate statistical significance as determined 
using the independent samples t-test.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001Cancer Cell International 2009, 9:21 http://www.cancerci.com/content/9/1/21
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nificantly downregulated in PC-3 and DU 145 cells, miR
24 was upregulated by about 2-fold in PC-3 cells and was
expressed at almost the same level in DU 145 cells as com-
pared to the expression in MDA PCa 2b cells (Figure 6A,
table 6). The miRNA expression profile is significantly dif-
ferent (p < 0.01, table 6) in the four PCa cell lines, thus
suggesting that miR 23b-24 cluster expression is not indic-
ative of the intrinsic androgen responsive status of PCa
cells. In all four PCa cell lines, miR 24 is the most abun-
dantly expressed member miRNA. The mature miR 24 is
also derived from a paralogous miR 23a-24 cluster on
chromosome 19 comprising of miR 23a, miR 27a and
miR 24. Hence, the level of miR 24 observed here presum-
ably represents the total miR 24 expression derived from
both paralogous clusters.
The expression of AMPO transcript was reduced by
approximately 13 fold in LNCaP, PC-3 and DU 145 cells
as compared to its expression in MDA PCa 2b cells (Figure
6B, table 6). This expression pattern matches the down-
regulation of all three member miRNAs of the miR 23b-24
cluster in LNCaP cells and the lower expression of miRs
23b and 27b in PC-3 and DU 145 cells as compared to the
expression in MDA PCa 2b cells (Figure 6A). Pearson cor-
relation analysis of the AMPO and miR 23b-24 expression
data suggests a positive correlation between the expres-
sion of AMPO gene and miRs 23b and 27b but no signif-
icant correlation between the expression of AMPO and
miR 24 (table 7). However, since the expression of miR 24
observed here could potentially represent the total miR 24
expression derived from miR 23b-24 cluster (residing in
AMPO gene on chromosome 9) as well as its paralogous
cluster miR 23a-24 (chromosome 19), the miR 24 expres-
sion may be disregarded in the interpretation of correla-
tion with the host gene expression.
Discussion
The objectives of this study were: (1) to determine if a sub-
set of miRNAs has a specific expression pattern in andro-
gen-sensitive and androgen-independent PCa cell lines;
(2) if there is a correlation in the expression levels of miR-
NAs and their host genes; and finally (3) to statistically
examine if the expression of these miRNAs can delineate
the intrinsic hormonal-sensitivity of the PCa cells studied
here.
Several miRNA expression profiling studies have identi-
fied unique, differential miRNA expression patterns in dif-
ferent cancer types leading to the successful use of miRNA
signatures for the molecular classification of cancer
[57,58]. Hence, it was pertinent to search for miRNA
expression profiles unique to androgen-dependent and
androgen-independent PCa cells. However, whether
miRNA expression profiles can predict the intrinsic andro-
gen sensitivity of PCa cells is still an open question. Only
a few studies so far have addressed the correlation, if any,
between miRNA expression and intrinsic androgen
responsive status of PCa cells. In this context, we investi-
gated the expression of 12 miRNAs organized in three
clusters (miR 17–92, miR 106b-25 and miR 23b-24) in
Quantitative real-time PCR expression profile of miR 17–92  cluster and the host transcript C13orf25 in prostate cancer  cell lines Figure 4
Quantitative real-time PCR expression profile of miR 
17–92 cluster and the host transcript C13orf25 in 
prostate cancer cell lines. (A) miRNA expression as 
determined by qRT-PCR. The relative expression of each 
miRNA is plotted as 2-ΔCt after normalization to sno66 
expression. Each bar represents mean ± SEM of at least 3 
replicates. (B) qRT-PCR analysis of C13orf25 mRNA expres-
sion. Each bar represents C13orf25 mRNA expression nor-
malized to GAPDH mRNA expression. Data are plotted as 
mean ± SEM of six replicates. (MDA = MDA PCa 2b).
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two androgen-dependent (MDA PCa 2b and LNCaP) and
two androgen-independent (PC-3 and DU 145) PCa cell
lines using northern blotting and qRT-PCR analysis.
Northern blot analysis pointed out unique differences
between the miRNAs of a given cluster. Some miRNAs
appear to have unique expression in androgen-dependent
and androgen-independent PCa cells (Figures 1, 2, 3,
table 1). However, since probes used for northern blotting
cannot distinguish between closely related miRNA
sequences, we relied on the analysis of data generated by
qRT-PCR. For all three miRNA clusters, member miRNAs
are most abundantly expressed in MDA PCa 2b cells and
are downregulated in LNCaP, PC-3 and DU 145 cell lines.
In the miR 17–92 cluster, the expression profile of all the
six member miRNAs in androgen-dependent MDA PCa
2b cells is significantly distinguishable from that in
another androgen-dependent cell line, LNCaP (Figure 4A
& table 2). Likewise, the expression profiles of miR 17–92
cluster members in PC-3 and DU 145 cells, both andro-
gen-independent PCa cell types, significantly differ from
each other (Figure 4A & table 2). This suggests that the
expression of the miR 17–92 cluster does not correlate
with the intrinsic androgen-responsive status of PCa cells.
Similarly, in the miR 106b-25 cluster (Figure 5A, table 4)
and in the miR 23b-24 cluster (Figure 6A, table 6), the
expression profiles of member miRNAs do not match in
either androgen-dependent cell lines (MDA PCa 2b and
LNCaP) or two androgen-independent cell lines (PC-3
and DU 145).
None of the host genes studied here appears to contain
consensus androgen responsive elements (ARE) and thus
may not be potential direct targets of AR mediated tran-
scriptional activation. To further confirm if host genes or
miRNAs may respond to noncanonical androgen signal-
ing, we treated LNCaP cells growing in charcoal stripped
serum with dihydrotestosterone (DHT) and measured the
expression of host genes and several miRNAs by qRT-PCR.
The comparison of the expression profiles in untreated
and DHT treated LNCaP cells did not demonstrate any
statistically significant variation (data not shown), sug-
gesting that the expression of host genes and miRNA clus-
ters is not influenced by hormone signaling.
Although with the set of miRNAs studied here, a unique
miRNA signature for androgen response status of PCa
cells was not identified, a few investigations have reported
the differential expression of miRNAs in androgen-
dependent and androgen-independent PCa cells. A recent
study suggested the potential of miRNA expression pro-
files to classify the clinical PCa samples according to their
androgen dependence [30]. Further, Galardi et al. [33]
reported that miR 221 and miR 222 are overexpressed in
PC-3 cellular model of aggressive PCa as compared with
LNCaP and 22Rv1 cell line models of slow growing carci-
nomas. These miRNAs were found to contribute to PCa
pathogenesis by targeting the tumor suppressor p27kip1.
Most recently, miR 146a and miR 125b were reported to
be differentially expressed in androgen-dependent PCa
cells as compared to their expression in androgen- inde-
pendent PCa cells [29,35]. Further investigations evaluat-
ing a large number of miRNAs are required to fully
address the question of potential association between
miRNA expression and intrinsic androgen sensitivity of
PCa cells.
The expression of the miRNA clusters examined in this
study has not been previously evaluated in PCa cells. Only
one report has shown the overexpression of miR 17-5p,
miR 20a (miR 17–92 cluster) and miR 25 (miR 106b-25
cluster) in prostate tumor samples [31]. With regard to the
Table 3: Pearson product-moment correlations of C13orf25 mRNA expression with the expression of resident miRNAs.
miR17-5p miR18a miR19a miR19b miR 20a miR 92a
C13orf25 Pearson correlation coefficient -0.343 -0.126 -0.004 -0.036 -0.098 -0.366
Significance (1-tailed) 0.329 0.437 0.498 0.482 0.451 0.317
*Correlation is significant at 0.01 level
Table 4: Fold changes in MCM7 mRNA and miR 106b-25 expressions in PCa cell lines.
LNCaP/MDA PC-3/MDA DU145/MDA PC-3/LNCaP DU145/LNCaP DU145/PC-3
MCM7 0.84 2.52**** 1.46** 2.97*** 1.72*** 0.58***
miR 25 0.40*** 0.70** 0.55** 1.75*** 1.35* 0.77**
miR 93 0.26**** 0.73** 0.42**** 2.72*** 1.58*** 0.58***
miR 106b 0.34**** 0.18**** 0.47**** 0.55*** 1.38** 2.50****
The fold change in the expression levels of mRNA and miRNAs was determined by ratios of the expression between two cell lines (LNCaP/MDA, 
PC-3/MDA, DU145/MDA, PC-3/LNCaP, DU145/LNCaP and DU145/PC-3). Asterisks indicate statistical significance as determined using the 
independent samples t-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001Cancer Cell International 2009, 9:21 http://www.cancerci.com/content/9/1/21
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expression of miR 23b-24 cluster in PCa, the downregula-
tion of miR 23b and miR 27b in clinical PCa samples as
compared to their expression in benign prostatic hyper-
plasia samples has been reported [30]. In the present
study, we observed intriguing differences in miRNA
expression across the four PCa cell lines. The most striking
observation in our data is the magnitude of fold differ-
ences in the expression of miRNA cluster members across
the four cell lines. The member miRNAs of the miR 17–92
cluster are downregulated by a range of 5 to 9 fold in
LNCaP cells as compared to their expression in MDA PCa
2b cells; in PC-3 cells, miRs 18a, 19a, 19b and 20a are
downregulated by 10–20 fold as compared to their
expression in MDA PCa 2b cells and in DU 145 cells,
downregulation of member miRNAs ranges from 4 to 8
fold (Figure 4A & table 2). Likewise, the member miRNAs
of miR 106b-25 cluster are downregulated by 2–5 fold in
LNCaP, PC-3 and DU 145 cells as compared to their
expression in MDA PCa 2b cells (Figure 5A & table 4). In
the miR 23b-24 cluster, the miR 24 expression measured
by qRT-PCR does not estimate the miR 24 expression
derived from miR 23b-24 cluster alone; instead, it repre-
sents the combined miR 24 expression from miR 23b-24
cluster and its paralog miR 23a-24 cluster present on chro-
mosome 19. This could explain the high expression of
miR 24 as compared to the expression of miRs 23b and
27b observed in our study. There is a highly significant
downregulation (1.5 to 12 fold) of miRs 23b and 27b in
LNCaP, PC-3 and DU 145 cell lines as compared to MDA
PCa 2b cell line (Figure 6A & table 6). It is reasonable to
speculate that such a magnitude of fold change in the
expression of miRNAs across the four PCa cell lines may
have significant biological consequences. It is possible
that these clustered miRNAs may be playing important
roles in the pathogenesis of PCa. In this context, some tar-
get mRNAs of the miR 17–92 cluster members have been
experimentally validated. These targets include both
tumor suppressors (p21, Bim, PTEN, Rb2/p130, Rbl2) as
well as oncogenes (E2F1, AIB1) suggesting that the miR-
NAs of the miR 17–92 cluster can act as both oncogenes
or tumor suppressors by modulating cell proliferation in
a cell-type-specific manner depending on the set of target
mRNAs that are expressed [42,49,59-62]. The experimen-
tally validated targets of miR 106b-25 cluster also include
the tumor suppressors, Bim and p21 as well as the onco-
gene, E2F1 [44,16]. Likewise, several mRNA targets of miR
23b-24 cluster, namely CYP1B1 and hALK4 have been
identified [52,63,64]. It would be interesting to evaluate
the expression of these targets in PCa cell culture models
and clinical samples.
A few studies have compared the expression profiles of
miRNAs and their host genes. Significant correlation
between miRNA and host gene expression was reported
suggesting the coregulation of intronic miRNA and host
gene expression [65,66]. In this study, we profiled both
Expression profiles of member miRNAs of miR 106b-25 clus- ter and the host gene MCM7 in prostate cancer cell lines Figure 5
Expression profiles of member miRNAs of miR 106b-
25 cluster and the host gene MCM7 in prostate can-
cer cell lines. (A) miRNA expression as determined by 
qRT-PCR. The relative expression of each miRNA is plotted 
as 2-ΔCt after normalization to sno66 expression. Each bar 
represents mean ± SEM of at least 3 replicates. (B) qRT-PCR 
analysis of MCM7 mRNA expression. Each bar represents 
MCM7 mRNA expression normalized to GAPDH mRNA 
expression. Data are plotted as mean ± SEM of six replicates. 
(MDA = MDA PCa 2b).
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Table 5: Pearson product-moment correlations of MCM7 mRNA expression with the expression of resident miRNAs.
miR 25 miR 93 miR 106b
MCM 7 Pearson correlation coefficient 0.089 0.216 -0.582
Significance (1-tailed) 0.455 0.392 0.209
*Correlation is significant at 0.01 levelCancer Cell International 2009, 9:21 http://www.cancerci.com/content/9/1/21
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the miRNA and host gene expression in four PCa cell
lines. A positive correlation was observed between the
expression of AMPO transcript and its resident miRs 23b
and 27b (table 7). No significant correlation was observed
between the expression of C13orf25 transcript and the
expression of its resident miR 17–92 cluster members
(table 3). Likewise the comparison of MCM7 mRNA
expression with the expression of its resident miR 106b-
25 cluster members shows no significant correlation
(table 5). This appears to be in contrast to a previous find-
ing which observed a perfect correlation between MCM7
mRNA expression and miR 106b-25 precursor miRNA
expression [16]. Interestingly, the levels of miR 106b-25
precursor miRNAs do not appear to correlate perfectly
with the levels of the mature forms of these miRNAs [16].
This observation is consistent with our findings as we
have quantified the mature forms of miRNAs in the study.
Although we have shown the absence of correlation
between the miRNA and the host transcript expression in
two out of the three miRNA clusters, it may be a wide-
spread phenomenon. Contrary to previous observations,
our results suggest that host gene expression may not be a
reliable indicator of the intronic miRNA expression. Our
findings raise interesting questions regarding the biogen-
esis of intronic miRNAs. Since the expression of intronic
miRNAs does not correlate with the expression of the host
transcript, could it be that instead of being derived from
the spliced intron of the host transcript, the resident miR-
NAs are transcribed independently from an alternative
promoter in response to intracellular signaling? Another
possibility could be that the resident miRNAs are co-tran-
scribed with the host gene but additional, yet unknown,
regulatory events occurring during the post-transcrip-
tional processing of primary miRNAs to mature miRNAs
may lead to diverse miRNA expression as compared to the
host gene expression.
Conclusion
In conclusion, we studied the expression of 12 miRNAs
from three clusters and compared their expression with
the host gene expression in androgen-sensitive and andro-
gen-refractory PCa cell lines. Our data indicate that the
expression of none of these 12 miRNAs correlates with the
androgen-dependent and androgen-refractory stages of
the PCa cell culture models. MDA PCa 2b cells were
unique in terms of overexpression of most of the miRNAs
studied here. More importantly, in two out of the three
miRNA clusters, we found no correlation between the
host gene expression and resident miRNA expression,
thus suggesting that the expression of some host genes
Table 6: Fold changes in the expressions of the host transcript AMPO and the resident miR 23b-24 cluster in PCa cell lines.
LNCaP/MDA PC-3/MDA DU145/MDA PC-3/LNCaP DU145/LNCaP DU145/PC-3
AMPO 0.02**** 0.03**** 0.07**** 1.69**** 3.24**** 1.91***
miR 23b 0.09**** 0.17**** 0.60**** 1.83**** 6.29**** 3.43****
miR 24 0.10**** 1.90**** 1.12 18.95**** 11.20**** 0.59****
miR 27b 0.07** 0.19** 0.33** 2.52** 4.23*** 1.67***
The fold change in the expression levels of the host gene and member miRNAs was determined by ratios of the expression between two cell lines 
(LNCaP/MDA, PC-3/MDA, DU145/MDA, PC-3/LNCaP, DU145/LNCaP and DU145/PC-3). Asterisks indicate statistical significance as determined 
using the independent samples t-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Differential expression of miR 23b-24 cluster and the host  gene AMPO in prostate cancer cell lines Figure 6
Differential expression of miR 23b-24 cluster and the 
host gene AMPO in prostate cancer cell lines. (A) 
miRNA expression as determined by qRT-PCR. The relative 
expression of each miRNA is plotted as 2-ΔCt after normaliza-
tion to sno66 expression. Each bar represents mean ± SEM 
of at least 3 replicates. (B) qRT-PCR analysis of AMPO 
mRNA expression. Each bar represents AMPO mRNA 
expression normalized to GAPDH mRNA expression. Data 
are plotted as mean ± SEM of six replicates. (MDA = MDA 
PCa 2b).
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and their resident miRNAs may be independent of each
other. Our findings indicate the possibility of novel regu-
latory mechanisms for the processing of intronic miRNAs.
Whether these mechanisms are cancer-specific is an open
question. Further investigations directed to evaluate the
complex phenomenon of intronic miRNA biogenesis in
cancer cells may lead to the identification of new thera-
peutic targets.
Methods
Cell Lines and Cell Culture
The androgen-dependent human PCa cell lines MDA PCa
2b and LNCaP, and androgen-independent PCa cell lines
PC-3 and DU145 were obtained from American Type Cul-
ture Collection (Manassas, VA). MDA PCa 2b cells were
cultured in BRFF-HPC1 medium (Athena Enzyme Sys-
tems, Baltimore, MD) supplemented with 20% fetal
bovine serum (FBS) and antibiotics (100 units/ml of pen-
icillin G sodium; 100 μg/ml streptomycin sulphate).
LNCaP, PC-3 and DU145 cells were cultured in RPMI
1640 medium supplemented with 10% FBS, 2 mM L-
glutamine and antibiotics. All cell lines were maintained
in a humidified 5% CO2 atmosphere at 37°C.
RNA Extraction
Total RNA was isolated from 80% confluent cells using
Trizol reagent (Invitrogen, Carlsbad, CA) according to
manufacturer's instructions. RNA yield and purity were
determined spectrophotometrically at 260–280 nm and
the integrity of RNA verified by electrophoresis through
denaturing agarose gels stained with ethidium bromide.
Northern Blotting
Total RNA samples (30 μg each) were separated on 15%
polyacrylamide gels containing 7 M urea and electroblot-
ted to nylon membranes (Hybond-XL, Amersham Bio-
sciences). After UV cross-linking the RNA to nylon
membrane at 120 mJ for 1 minute, the membrane was
prehybridized in 10 ml ULTRAhyb-Oligo hybridization
buffer (Ambion) at 35°C for 30 minutes and then,
hybridized in the same buffer with γ-32P labelled probes at
35°C overnight. DNA oligonucleotides complementary
to mature miRNAs and U6 small nuclear RNA (snRNA)
were used as probes. Probes were 5' end-labelled using [γ-
32P] ATP and T4 polynucleotide kinase (Promega, Madi-
son, WI). After overnight hybridization, the membrane
was washed twice with 6× SSC for 15 minutes and 0.1%
SDS with 6× SSC for 10 minutes, each at room tempera-
ture and then exposed to phosphor screen overnight.
Bands were visualized by scanning the screens on
Typhoon 9410 Variable Mode Imager (Amersham Bio-
sciences). Expression of U6 snRNA was used as a loading
control. Blots were stripped by incubating in 1% SDS at
65°C for 1 hour and reprobed.
Reverse Transcription and Quantitative Real-Time (qRT) 
PCR Analysis of Mature miRNA Expression
First strand cDNA was synthesized from 10 ng of total
RNA using primers specific for mature miRNAs and small
nucleolar RNA 66 (sno66). The miRNA-specific primers
were obtained from TaqMan MicroRNA Assays (Applied
Biosystems Foster City, CA). Reagents for cDNA synthesis
were obtained from TaqMan MicroRNA Reverse Tran-
scription kit (Applied Biosystems). For each sample, a 15
μl reverse transcription (RT) reaction was set up contain-
ing 10 ng of total RNA, 1× RT buffer, 1 mM of dNTP mix,
50 units of MultiScribe reverse trancriptase, 3.8 units of
RNase inhibitor and 3 μl of miRNA-specific RT primer.
The reactions were incubated in a thermal cycler (BIORAD
PTC-100) at 16°C for 30 minutes, 42°C for 30 minutes,
85°C for 5 minutes and then held at 4°C. The 'reverse
transcriptase minus' controls were also synthesized under
the same conditions. In order to quantify the mature miR-
NAs and sno66 in each sample, the cDNAs were amplified
using TaqMan MicroRNA Assays together with the Taq-
Man 2× Universal PCR Master Mix (Applied Biosystems
Foster City, CA). Briefly, a 20 μl reaction was set up con-
taining 1.33 μl product from RT reaction, 1 μl of 20× Taq-
Man microRNA assay mix (mixture of miRNA-specific
forward and reverse primers, and miRNA-specific TaqMan
MGB probe labeled with FAM fluorescent dye) and 10 μl
of TaqMan 2× Universal PCR Master Mix. These reactions
were dispensed into a 96-well optical plate and the plate
was positioned in 7500 Real-time PCR System (Applied
Biosystems) under the following conditions: 95°C for 10
minutes followed by 40 cycles of 95°C for 15 seconds and
60°C for 1 minute. Three replicates were performed per
RT reaction together with the 'reverse transcriptase minus'
and 'no template' controls. Duplicate PCRs were per-
formed for all miRNAs in each RNA sample. The mean Ct
was determined from the replicates. Sno66 expression was
used as an invariant control. The relative expression of
each miRNA was calculated as 2-ΔCt where ΔCt = Ct value
of each miRNA in a sample – Ct value of sno66 in that
Table 7: Pearson product-moment correlations of AMPO mRNA expression with the expression of resident miRNAs.
miR 23b miR 24 miR 27b
AMPO Pearson correlation coefficient 0.871 -0.013 0.978*
Significance (1-tailed) 0.065 0.494 0.011
*Correlation is significant at 0.05 levelCancer Cell International 2009, 9:21 http://www.cancerci.com/content/9/1/21
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sample. All experiments were repeated at least twice with
three replicates and two independent RNA samples. All
replicates provided similar results.
Quantitative Real-Time PCR Analysis of Host Gene 
Expression
Total RNA was isolated from the cells as described above.
To remove DNA contamination from the RNA samples,
10 μg of total RNA was incubated with 10 units of DNase
I (Amplification grade; Invitrogen, Carlsbad, CA) at 37°C
for 30 minutes. 1 μg of DNase I treated RNA was reverse
transcribed into cDNA using the ImProm-II Reverse Tran-
scription System (Promega, Madison, WI). Briefly, a 20 μl
RT reaction was set up containing 1× ImProm-II reaction
buffer, 5.5 mM MgCl2, 0.5 mM of each dNTP, 20 units of
RNasin ribonuclease inhibitor, 0.5 μg of oligo (dT15)
primer, 1 μl of ImProm-II reverse transcriptase and 1 μg of
RNA. The RT reactions were incubated at 25°C for 5 min-
utes followed by 42°C for 1 hour and reverse transcriptase
was inactivated by heating at 70°C for 15 minutes. Prim-
ers for real-time PCR were designed using the Primer
Express software (v3.0; Applied Biosystems). The SYBR
Green ER qPCR SuperMix Universal was obtained from
Invitrogen and used for setting up real-time PCR reac-
tions. In brief, a 20 μl reaction was set up containing 1×
SYBR Green Supermix (Invitrogen), 0.05 μM of each of
the forward and reverse primers, 50 nM ROX dye and 2 μl
of template cDNA. The reactions were dispensed into 96-
well optical plates and the amplification was carried out
in 7500 Real-time PCR System (Applied Biosystems)
under the following conditions: 50°C for 2 minutes,
95°C for 10 minutes followed by 40 cycles of 95°C for 15
seconds and 60°C for 1 minute. Three replicates were per-
formed per cDNA sample along with the 'reverse tran-
scriptase minus' and 'no template' controls. Each PCR
with three replicates was repeated twice. The specificity of
amplification was confirmed by melting curve analysis
and also by running the PCR reactions on 3% agarose gels.
Gene expression was quantified using the relative stand-
ard curve method. Different dilutions of cDNA synthe-
sized from HeLa cells were used to plot the standard
curves for each gene. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) expression was used as an internal
control and the relative expression of each gene was nor-
malized to GAPDH expression. Mean normalized expres-
sion of each gene ± SE was calculated from the PCR
replicates. All experiments were repeated at least twice
with three replicates and two independent RNA samples
and similar results were obtained. Following primers were
used for the host gene expression analysis: (i) C13orf25
Forward ACACGCGGCCAGGTTAAG, Reverse CGCT-
GCAAAGATCGTTTGAG; (ii) MCM7 Forward CATGAG-
GCGTTACATAGCCATGT, Reverse CTCTCGCC TCATC
TCCACGTA; (iii) AMPO Forward GGCCATGGGTGTGTA
CCTCTA, Reverse GACCTATCCATCTGCTCCTTGGT; (iv)
GAPDH Forward ACCCACTCCTCCACCTTTGAC, Reverse
TGTTGCTGTAGCCAAATTCGTT.
Statistical Analysis
The statistical analysis of expression levels of 12 miRNAs
and three host precursor mRNAs and their coexpression in
PCa cell lines was performed utilizing the SPSS package.
The index of expression of each miRNA was 2-ΔCt after nor-
malization to sno66 expression levels. The following anal-
yses were conducted:
(i) Pairwise comparison of miRNAs selected from three
clusters (17–92, 106b-25, 23b-24) across four PCa cell
lines using independent samples t-test.
(ii) Pairwise comparison of the three selected host genes
across four PCa cell lines using independent samples t-
test.
(iii) The degree of linearly related expression levels
between the host gene and resident miRNAs was deter-
mined by Pearson product-moment correlation coeffi-
cients.
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